Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-17T02:18:13.757Z Has data issue: false hasContentIssue false

“Continuous” Thioproperazine

A Controlled Trial in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

E. C. MacLeod
Affiliation:
Department of Psychological Medicine, Southern General Hospital, Glasgow; Glasgow Royal Mental Hospital
J. Moffat
Affiliation:
Glasgow Royal Mental Hospital
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Thioproperazine (‘Majeptil’) is a recently introduced phenothiazine derivative which readily produces extra-pyramidal disturbances. Its pharmacology was originally described by Courvoisier et al. (1958) and its clinical properties by a number of workers including, in this country, Denham and Carrick (1961). Several investigators have reported impressive results with this drug in a variety of mentally ill patients, including chronic schizophrenics who had failed to respond to other forms of therapy.

Information

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1963

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.